Overexpression of VEGFRs, particularly VEGFR-2, has been significantly associated with low survival rates in patients with sarcomas44–48, and VEGF/VEGFR-targeted therapy is thus indicated for sarcoma based on its effects on angiogenesis. This evidence concerns the gene VEGFA and sarcoma.